The first ever approval of a new kind of cancer immunotherapy called CAR-T is one step closer. A 10-member panel of doctors and researchers who advise the Food and Drug Administration recommended with a rare unanimous vote that the agency approve... Read more »
Austin—Clearhead, which helps companies “personalize” digital tools used by their customers, has been acquired by Accenture (NYSE: ACN).
The Austin, TX-based company has developed data analytics software that helps its customers, who are companies such as USAA and CVS... Read more »
With influenza season a few months away, Sanofi is giving its vaccine operations a shot in the arm by acquiring Protein Sciences, a company that has a commercial vaccine, Flublok, and manufactures it using genetic engineering and cell culture instead of... Read more »
[Updated 7/12/17, 8:38 am, to add MoneyTree data. See below.] U.S. venture capital investments are showing more signs of returning to steady levels.
Investors pumped $21.78 billion into 1,958 companies in the second quarter, according to data from the... Read more »
Two days before a panel of the FDA’s outside advisors grill Novartis about its groundbreaking cell therapy under review, agency staffers released their own assessment of the product, which now goes by the name tisagenlecleucel.
If approved for kids and... Read more »
The Fourth of July was this week, but members of Congress didn’t need to crane their necks skyward to see fireworks. Senators returned to their districts, where local news offered blistering headlines about the potential impact of the Republican plan to... Read more »
Celgene wants a shot at a bigger slice of the global cancer drug market, and the company is turning to China to do it. Summit, NJ-based Celgene has reached a deal with BeiGene, based in Beijing, for rights to a cancer... Read more »
Nearly a month after Merck paused enrollment in three clinical trials in multiple myeloma to gather more information about patient deaths, the FDA has now put a stop to those studies altogether.
Merck (NYSE: MRK) said Wednesday that the FDA... Read more »